I tend to agree, but for the record, SGEN does have the 'poison pill' capability to fend off a hostile takeover. From the 10Q:
Our Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the stockholders, which authority could be used to adopt a “poison pill” that could act to prevent a change of control of Seattle Genetics that has not been approved by our Board of Directors. The rights of the holders of common stock may be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Seattle Genetics without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. Further, certain provisions of our charter documents, including provisions eliminating the ability of stockholders to take action by written consent and limiting the ability of stockholders to raise matters at a meeting of stockholders without giving advance notice, may have the effect of delaying or preventing changes in control or management of Seattle Genetics, which could have an adverse effect on the market price of our stock. In addition, our charter documents provide for a classified board, which may make it more difficult for a third party to gain control of our Board of Directors. Similarly, state anti-takeover laws in Delaware and Washington related to corporate takeovers may prevent or delay a change of control of Seattle Genetics.
Llabtech, There is one little company trying something like you mentioned GNSZ. I haven't studied it very well, seems they are self promoting a bit too much. In a phase I trial. I do keep an eye on it. I have no position in her.
As news hits and collaborations continue you will stand to gain so much more. A year here is not enough time but you should always reevaluate your investment.
Without any great catalyst the stock has been gaining momentum and is following the plans Clay set out. Too many biotechs are like kids in a candy store wanting to do too much without the cash. SGEN is doing it with their cash reserves and income rather than dilution, gains in their space and how to expand it, working with many of the big pharmas.
Until we find that the platform can not be expanded or has limitations, I would bet on SGEN making great strides. IMHO